According to the new market research report, "Human Organoids Market by Product (Pancreas, Kidney, Lung, GIT, Liver Models) Usabilty (Customized, Ready-To-Use), Application (Toxicity, Pathology, Personalized & Regenerative Medicine), Enduser (Pharma-Biotech, CROs, Academia) & Region- Global Forecast to 2025", The global human organoids market size is estimated to be USD 850 million in 2020 and projected to reach USD 1,901 million by 2025, at a CAGR of 17.5 %.

Browse and in-depth TOC on "Human Organoids Market"
143 - Tables
23 - Figures
174 - Pages

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Global Industry Growth Boosting Factors:

Increasing prevalence of transplantation, technological advancements and increased funding and public-private investments are the key factors driving the growth of the human organoids.

By product, liver segment is expected to have the largest market share during the forecast period

The large share of this segment is attributed to factors such as the significant adoption of new technologies among researchers and academia (coupled with growing industry-academia collaborations for genomic research), technological advancements in the field of 3D bioprinting and the increased number of liver tranplants and diseases.

Delelopmental biology is the largest application segment of the human orgnaoids market

Developmental biology includes the production of gametes, fertilization, development of the embryo, emergence of the adult organism, and senescence. Organoids developed from stem cells or tissues in culture can be converted into structures that resemble the in vivo anatomy and physiology of intact organs. Human organoid cultures provide the potential to study the human development and model disease processes with the same depth of analysis customary for research with nonhuman model organisms. Technological advancements in the field of 3D bioprinting have shown huge potential for organ development as the culture time is very less compared to traditional methods of tissue culture. Patient-derived human organoid studies may accelerate medical research, creating new opportunities for tissue engineering and regenerative medicine and generating knowledge and tools for preclinical studies, including drug development and testing.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Pharceuticals & Biotechnology companies accounted for the largest share of the human organoids market, by end users, in 2020

Pharmaceutical and biotechnology companies mainly focus on developing new drugs for the treatment of various rare diseases. These companies need to submit specific data related to drug development during the drug development process and subsequent filing of applications to regulatory bodies. This necessitates a wide spectrum of services in the early development phases and clinical phases to comply with regulatory requirements. Technical and regulatory challenges related to the development of new drug molecules create complexities for pharmaceutical and biotechnology companies in terms of time and cost. However, due to strict regulations, companies often produce technologically superior products with better safety norms.

North America is the largest regional market for Human Organoids

North America (comprising the US and Canada) dominates the human orgnaoids market. North America is a mature market, with high penetration of human organoids technologies among key end users (pharmaceuticals & biotechnology companies, CROs, academia and others) and well-established distribution channels for human organoids product manufacturers and suppliers. Easy accessibility to and the high adoption of advanced technologies due to the significant per capita annual healthcare expenditure by the US and Canadian governments, as well as supportive government regulations, are driving the growth of the human organoids market in this region.

Key Market Players
BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).

Speak to Analyst@ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=171046468

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: [email protected]